Omalizumab has shown to be effective in patients with other comorbid allergic conditions such as ABPA, food allergy, nasal polyposis, etc., in whom high IgE levels (IgE >1500 IU/mL) were reported; hence, they should be taken into consideration during the therapeutic management of allergic asthma. The gene discussed is IGHE; the disease is Nasal polyposis.